Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Value Market Research | PRODUCT CODE: 1457981

Cover Image

PUBLISHER: Value Market Research | PRODUCT CODE: 1457981

Global Lenalidomide Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

PUBLISHED:
PAGES: 171 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3920
PDF (10-user License)
USD 4730
PDF (Corporate User License)
USD 7430

Add to Cart

The global demand for Lenalidomide Market is presumed to reach the market size of nearly USD 31.3 Billion by 2032 from USD 18.23 Billion in 2023 with a CAGR of 6.19% under the study period 2024 - 2032.

Lenalidomide is a medication used in the treatment of certain cancers, particularly multiple myeloma and myelodysplastic syndromes. It belongs to a class of drugs known as immunomodulatory agents, working to modify the immune system's response and inhibit the growth of cancer cells. lenalidomide is often prescribed in combination with other therapies for improved efficacy.

MARKET DYNAMICS

The lenalidomide market is witnessing significant growth, driven by the expanding prevalence of hematological malignancies, particularly multiple myeloma and myelodysplastic syndromes. Lenalidomide, an immunomodulatory drug, has demonstrated efficacy in treating these conditions, leading to increased adoption in clinical settings. Furthermore, ongoing research and development activities explore the drug's potential for treating various cancers, contributing to its market expansion. Additionally, favorable reimbursement policies and a growing awareness of the drug's therapeutic benefits foster market growth. The rise in aging populations globally, which is a significant demographic factor linked to these hematological disorders, is further fueling the demand for this medication. However, certain factors, such as stringent regulatory requirements and potential adverse side effects, will likely hamper the lenalidomide market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of lenalidomide. The growth and trends of lenalidomide industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the lenalidomide market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

  • 5Mg Capsules
  • 10Mg Capsules
  • 15Mg Capsules
  • 25Mg Capsules

By Application

  • Multiple Myeloma (MM)
  • Myelodysplastic Syndromes (MDS)
  • Other Applications

By End-User

  • Hospitals
  • Cancer Treatment Centers
  • Research Institutes

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Lenalidomide market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

  • GLOBAL LENALIDOMIDE MARKET SHARE BY REGION (REPRESENTATIVE GRAPH)
  • Global Lenalidomide Market Share

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Lenalidomide market include Accord Healthcare, Cipla, Deva Pharma, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals, Hetero, Hikma Pharmaceuticals, Lupin Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113967

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . LENALIDOMIDE - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By End-User
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY TYPE

  • 5.1 Overview by Type
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Type
  • 5.4 5mg Capsules Historic and Forecast Sales by Regions
  • 5.5 10mg Capsules Historic and Forecast Sales by Regions
  • 5.6 15mg Capsules Historic and Forecast Sales by Regions
  • 5.7 25mg Capsules Historic and Forecast Sales by Regions

6 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY APPLICATION

  • 6.1 Overview by Application
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Application
  • 6.4 Multiple Myeloma (MM) Historic and Forecast Sales by Regions
  • 6.5 Myelodysplastic Syndromes (MDS) Historic and Forecast Sales by Regions
  • 6.6 Other Applications Historic and Forecast Sales by Regions

7 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY END-USER

  • 7.1 Overview by End-User
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by End-User
  • 7.4 Hospitals Historic and Forecast Sales by Regions
  • 7.5 Cancer Treatment Centers Historic and Forecast Sales by Regions
  • 7.6 Research Institutes Historic and Forecast Sales by Regions

8 . GLOBAL LENALIDOMIDE MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE LENALIDOMIDE COMPANIES

  • 9.1. Lenalidomide Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF LENALIDOMIDE INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Accord Healthcare
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Cipla
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Deva Pharma
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Dr. Reddy's Laboratories Ltd.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Glenmark Pharmaceuticals
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Hetero
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Hikma Pharmaceuticals
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Lupin Limited
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Sun Pharmaceutical Industries Ltd.
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Teva Pharmaceutical Industries Ltd.
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Torrent Pharmaceuticals Ltd.
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments
  • 10.14. Viatris Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Company Revenue
    • 10.14.3. Products
    • 10.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

Product Code: VMR112113967

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Type (USD MN)
  • 5mg Capsules Market Sales by Geography (USD MN)
  • 10mg Capsules Market Sales by Geography (USD MN)
  • 15mg Capsules Market Sales by Geography (USD MN)
  • 25mg Capsules Market Sales by Geography (USD MN)
  • Analysis Market by Application (USD MN)
  • Multiple Myeloma (MM) Market Sales by Geography (USD MN)
  • Myelodysplastic Syndromes (MDS) Market Sales by Geography (USD MN)
  • Other Applications Market Sales by Geography (USD MN)
  • Analysis by End-User (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Cancer Treatment Centers Market Sales by Geography (USD MN)
  • Research Institutes Market Sales by Geography (USD MN)
  • Global Lenalidomide Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Lenalidomide Report
  • Market Research Process
  • Market Research Methodology
  • Global Lenalidomide Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by End-User
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Type (USD MN)
  • 5mg Capsules Market Sales by Geography (USD MN)
  • 10mg Capsules Market Sales by Geography (USD MN)
  • 15mg Capsules Market Sales by Geography (USD MN)
  • 25mg Capsules Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Multiple Myeloma (MM) Market Sales by Geography (USD MN)
  • Myelodysplastic Syndromes (MDS) Market Sales by Geography (USD MN)
  • Other Applications Market Sales by Geography (USD MN)
  • Global Market Analysis by End-User (USD MN)
  • Hospitals Market Sales by Geography (USD MN)
  • Cancer Treatment Centers Market Sales by Geography (USD MN)
  • Research Institutes Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!